Key subgroups

At Week 16, SOTYKTU demonstrated higher PASI 75 responses vs. placebo and vs. apremilast.^1,2 Subgroup effects were not identified³

Age

Gender

Race

No statistical difference vs. apremilast for Black/African-American

Duration of disease

Body weight

Prior systemic / biologic treatment

Disease severity

PASI, Psoriasis Area and Severity Index.

Subgroup analysis of pooled PSO-1/PSO-2 studies: patient characteristics at Week 16⁴

The results from the subgroup analysis need to be interpreted with caution and further investigation is required to confirm the trend in these results.

Age

	vs. placebo	vs. apremilast
<40 y	52.7 (44.8–60.5)	28.5 (18.9–38.0)
40–65 y	39.5 (33.6–45.4)	12.6 (4.9–20.2)
≥65 y	46.4 (32.3–60.5)	5.9 (–13.4 to 25.2)

Race

	vs. placebo	vs. apremilast
White	43.0 (38.2–47.8)	14.7 (8.6–20.9)
Asian	58.3 (45.2–71.4)	38.7 (21.4–56.0)
Black/AA	32.9 (–2.8 to 68.6)	-7.2 (–44.2 to 29.8)

Sex

	vs. placebo	vs. apremilast
Male	42.5 (37.2–47.7)	17.7 (10.7–24.7)
Female	48.1 (39.8–56.4)	17.6 (7.9–27.3)

Weight

	vs. placebo	vs. apremilast
<90 kg	46.9 (40.4–53.5)	19.9 (11.9–27.9)
≥90 kg	41.8 (35.9–47.7)	14.3 (6.1–22.4)

Adapted from Gooderham M et al. 2021.
Data represent the estimated difference and corresponding 95% CI.
Pooled PSO-1/PSO-2: SOTYKTU (n=843), apremilast (n=422), placebo (n=421).

Missing data were imputed with NRI.
AA, African-American; CI, confidence interval; NRI, non-responder imputation; y, years.

Subgroup analysis of pooled PSO-1/PSO-2 studies: previous therapy at Week 16⁵

The results from the subgroup analysis need to be interpreted with caution and further investigation is required to confirm the trend in these results.

A graph showing the Subgroup analysis of pooled PSO-1/PSO-2 studies

Adapted from Warren RB et al. 2021.
Pooled PSO-1/PSO-2: SOTYKTU (n=843), apremilast (n=422), placebo (n=421).

An icon representing pinch to zoom Pinch & zoom to explore

Missing data were imputed with NRI.
APR, apremilast; CI, confidence interval; IL, interleukin; NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index; PBO, placebo; TNF, tumour necrosis factor.

Subgroup analysis of pooled PSO-1/PSO-2 studies: disease severity at Week 16⁶

The results from the subgroup analysis need to be interpreted with caution and further investigation is required to confirm the trend in these results.

A graph showing the subgroup analysis of pooled PSO-1/PSO-2 studies: disease severity at Week 16

Adapted from Data on file.
Pooled PSO-1/PSO-2: SOTYKTU (n=843), apremilast (n=422), placebo (n=421).

An icon representing pinch to zoom Pinch & zoom to explore

Missing data were imputed with NRI.
BSA, body surface area; CI, confidence interval; NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index; sPGA, static Physician’s Global Assessment.

References

Armstrong A et al. J Am Acad Dermatol. 2023;88(1):29–39. Plus supplementary material.
Strober B et al. J Am Acad Dermatol. 2023;88(1):40–51. Plus supplementary material.
SOTYKTU. Summary of Product Characteristics.
Gooderham M et al. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy by Prespecified Baseline Demographics in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. Presented at EADV 30th Congress (Virtual); 29 September—2 October 2021.
Warren RB et al. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Prior Treatment in the Phase 3 POETYK PSO-1 and PSO-2 Trials. Presented at EADV Annual Congress 2021. Presentation: FC03.06.
Data on File. BMS